Introduction
Antibiotic resistance has reached alarming levels and represents one of the biggest current global threats to health. [1] There is an urgentn eed for new antimicrobial agents that allows us to tackle this problem in innovative ways.
Antimicrobial peptides (AMPs) have been identified as importantl eads for the next generation of antibiotics.
[1b, 2] The significant advantage of AMPs resides in the globalm echanism of their action, which is significantly different from those of conventional antibiotics.
[1d] AMPs display multifunctional properties, with implications fort heir application as potential therapeutic agents, because they representa ne ssential component of innate immunity. [3] They exhibit rapid killing, with ab road spectrum of activity against al arge array of microorganisms including Gram-positive and Gram-negative bacteria, fungi and protozoan and metazoan parasites. [1b, 4] The unique and diverse group of AMPs is divided into several subgroups, on the basis of amino acid composition and structure.
[1c, 4c] Linear,c ationic AMPs displayanumber of common characteristics including low molecular weight (10-50 amino acids) and amphiphilicity.T he latter arises from the high content of positively charged amino acids (lysine,a rginine, overall chargeg enerally from + 2t o+ 9) along with as ubstantial proportion of hydrophobic residues (! 30 %). [2b, 5] Both of these are key structuralf eatures that guidet he antimicrobial effects of these peptides.
The electrostatic repulsion between the chargeds idec hains renders the solution structureso ft he majorityo fc ationic AMPs intrinsically disordered (ID) with no discernible secondary structure.
[1c, 5a, 6] Upon membrane binding, an unstructured AMP undergoes ac onformational change and folds into aw ell-orAntimicrobial peptides (AMPs) kill bacteria by targeting their membranes through various mechanisms involving peptide assembly,o ften coupled with disorder-to-order structural transition. However,f or several AMPs, similar conformational changes in cases in which small organic compounds of both endogenous and exogenous origin have induced folded peptide conformationsh ave recently been reported. Thus, the functiono fA MPs and of natural host defence peptides can be significantly affected by the local complex molecular environment in vivo;n onetheless, this area is hardly explored. To address the relevance of such interactions with regardt os tructure and function, we have tested the effectso ft he therapeutic drug suramin on the membrane activity and antibacterial efficiency of CM15,apotent hybrid AMP.T he results provided insight into ad ynamic system in which peptide interaction with lipid bilayers is interferedwith by the competitive binding of CM15 to suramin, resulting in an equilibrium dependent on peptide-to-drug ratio and vesicles urface charge. In vitro bacterial tests showed that when CM15·suramin complex formation dominates over membrane binding, antimicrobial activity is abolished. On the basis of this case study,i ti sp roposed that small-molecule secondary structure regulators can modify AMP functiona nd that this should be considered and could potentially be exploited in future development of AMP-based antimicrobial agents.
dered-mostly a-helical-structure. [7] Because these peptides exert their action within the membrane environment, the membrane-associated conformational transition is believed to be ac rucial step in mediating their biological activities. This structuralt ransition could also be dependent on the lipid composition, leadingt oi ncreased specificity towards membranes enriched in negatively charged species. [1d, 8] However,t he in vivoa ction of these peptides is ac omplex issue, possibly including numeroust ypes of interactions with small-molecule agents. Indeed, previouss tudies in our group have suggestedt hat small molecules of both endogenous and synthetic origin can dramatically affect the structures of AMPs, potentially alteringt heir mechanistic function, including their antimicrobial efficiency. [5a, 9] Similarly,i th as also been observed that severald isordered AMP and protein sequences adopt ordered secondary structures induced by the lipid mediator lysophosphatidic acid; [10] this indicates that the presence and use of such interactions might be widespreadi no rganisms, a phenomenon far from being understood.
To shed more light on this issue, this study has focused on CM15, as hort, linear,n atively unfolded, synthetic hybrid AMP combined from the silk mothc ecropin Aa nd the bee venom peptidem elittin. CM15 displays ap otent broad-spectrum antimicrobial activity,r etainingt he bactericidal effect of cecropins but lacking the strongh aemolyticp roperty of melittin. [3, 5a, c, 9] With at otal charge of + 6, it has am uch highera verage charge per residue than its congeners. The highlyc ationic Nterminal region and am ostly hydrophobic C-terminal region separatei nto ah ydrophilic and ah ydrophobic part upon helix formation (Scheme 1) coupled to membranei nteraction. On the basis of the above factors, CM15 was used as amodel peptide for preliminary screening of folding inducer effectso f anionic drugs andb iomolecules.
[5a] Of the biomolecules and synthetic compounds tested on CM15, the therapeutic drug suramin was the most potent helix promoter, [5a] and so it was selected for this study as the most suitable candidate for addressingt he more complex AMP-small molecule-lipid bilayer interactions. Suramin is as ymmetrical, hexasulfonatedn aph-t hylureau sed since1 920 [11] as an anthelmintic, for treating onchocerciasis (African river blindness) [12] and sleeping sickness (African trypanosomiasis). [13] Suramin also shows anticancer and antiviral properties. [12a, 14] Using in vitro binding and functional assays, we characterised the interaction network of the CM15/suramin/membrane system.T he results indicate that the drug affects not only the secondary structure of the AMP buta lso its membrane activity, and that this finally results in decreased antibacterial activity. This observation implies that as yet undetected side effects might be identifiedw hen drugs with similar characteristics are administered. Alternatively,i ti sa lso hoped that the insight gainedm ight provide ap otential aspectt oe xploit in the development of new strategies, in which AMP functionm ight be alteredo re ven increased in ac ontrollable manner. Gothenburg, Sweden (2008 . As aMarie-Skłodowska Curie fellow he returned to Budapest in 2015, leading the Biomolecular Self-Assembly group under the "Momentum" excellence programme of the Hungarian Academy of Sciences. His research involves investigation of natural and nonnatural peptide assemblies, enzyme catalysis, polarised light spectroscopy and membrane-biomolecule interactions.
Results and Discussion
Circular dichroism study of structural changes in CM15 in the presence of suramin and liposomes As previously reported,
[5a] the drug suramin (Sur) has proved to be an effective folding inducerwith the disordered membraneactive peptide CM15. To aid understanding of the structural effects of suramin on the interaction between CM15 and membranes, CD spectra in the presenceo ft he interacting partners were collected.
The far-UV CD spectrum of free CM15 measured in buffer, with as ingle negative band at around 198-200 nm and no significant shoulder in the 210-230nmr egion, indicates an intrinsically disordered state ( Figure 1A ). This is in agreement with reported observations. [5a, 16] On the basis of the results presented here and in previous studies, [5a] suramin triggerst he disorder-to-order conformational transition of CM15. The characteristic positive/negative couplet corresponding to p-p* transitions at 195 and 208 nm, as well as the negative band due to the n-p*t ransition at 222 nm ( Figure 1A ), suggest ahelical folding of CM15. [17] Secondary structure analysisa lso indicatesi ncreased helix content( Ta ble S1 in the Supporting Information).
[5a] These spectralt ransformations occurred promptly after additiono ft he drug and are related to rapid interaction.
Moreover,t he relatively weakC Ds ignals might be indicative of complex formation accompanied by aggregation;t his has been verified by dynamic light scattering (DLS) measurements detecting particles on the micrometre scale.
[5a] It is to be noted that the intensity ratio of the CD values at 222 and 208 nm is below % 0.9 for non-interacting a-helices.I nl ine with CD data, this value is > 1f or the CM15/suramin mixture ( Figure 1A ), thus suggesting oligomerisation of the peptidec hains. In view of the net charges of + 6a nd À6o fC M15 and suramin, respectively,n eutral1 :1 complexes could easily assemble into higher oligomers or aggregates as suggested previously.
[5a]
Structural order gained upon interaction with membranes was probedw ith dioleoyl-phosphatidylcholine (DOPC, or PC) and dioleoyl-phosphatidylglycerol( DOPG, or PG) liposomes, mimicking electrostatic features of mammalian and bacterial biomembranes,r espectively.A ddition of neutral PC liposomes to CM15 caused the main negative band of the peptidet ob e red-shifted (from 198 to 203 nm), togetherw ith an intensity decrease, and the unresolved negative shoulder at 222 nm to becomem ore pronounced( Figure 1A ). This partial helical folding could be the result of aw eak, rather hydrophobic interaction lacking electrostatic attraction between the zwitterionic lipids and the peptide.
[5b] The outer leaflet of the mammalian cell membrane is exclusively composed of neutral, zwitterionic phospholipids, towards which charged peptides such as CM15 show lower affinity; [18] that is also why ionic AMPs are less toxic towards mammaliancells. [4c, 8b, c] In contrast, upon addition of negatively charged PC/PG liposomes, the ID peptidef olds into ad efinite helical conformation( Figure 1A ). Helix formation is also supported by the estimated % 40 %h elix content for the lipid-loaded CM15 ( Figure 1B and Ta ble S1). In this case, the driving force behind the folding could be the combination of electrostatic interactions between the positively chargedr esidues of the peptidea nd the negatively charged PG head groups,a sw ell as hydrophobic interactions between the nonpolars ide chains and the hydrophobic core of the lipid bilayer.
[5b, 18] To test the effect of suramin on lipid-bound peptide, titration with the drug was carried out in the presence of model membranes. In sharp contrastt ot he case of the free peptide, where addition of the drug resulted in elevated helix content, which saturated at 1:1m olar ratio, for the lipid-bound CM15, the suramin dependence was remarkably different( Figure 1B) . With increasing suramin concentration,t he helix content first reduced below the value of the lipid-free state in both types of vesicles, and this was then followed by as ignal increaser esultingi na na pproximately doubled helix fraction at 1:2m olar ratio, relative to the suramin-free state ( Figure 1B ). However, Figure 1 . Structuralchanges of CM15i nt he presence and in the absence of model membranes and suramin, studied by CD spectroscopy. A) Far-UVCDs pectra were takena tp eptide, suramin and lipid concentrationso f40, 40, and 635 mm,respectively. B) Effect ofs uramin on the helix content of free and membrane-bound CM15. The peptide (40 mm)w as titrated with suramin in the absencea nd in the presence of liposomes (635 mm total lipid) with use of CD buffer or PBS (for the compositions see the Experimental Section). Helix contentwas estimated witht he aid of the BestSel online tool. [30] Data are means AE SEMs, two series of titrations were carriedo ut with CD buffer,and as ingle titrationi nPBS was performed as acontrol. www.chembiochem.org 2019 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim differences betweent he two liposomet ypes were also revealed. For the neutralP Cs ystem, the helicalc ontent rose at high suramin ratios (> 60 mm,F igure 1B). The phenomenon could be explained in terms of nonspecific association of suramin above at hreshold concentration on the lipid bilayer rendering the neutral surfacen egativelyc harged, and this might facilitatepeptide binding and induce helical folding.
It should also be noted that titration curves followingt he same trend were obtained both in the presence and in the absence of sulfate ions, resembling drug sulfonate groups (Figure 1B) . Thus, it is evident that the sulfate moiety alone is not enough to trigger the peptidec onformational changes induced by suramin, in whichr elative spatial arrangemento ft he negatively charged groups as well as the separating rings act in concert.
Altogether,t hese findings suggest that suramin interacts with CM15 even in the presence of lipid bilayers and governs peptidec onformationi naconcentration-dependentm anner. For examination both of peptide structuralc hanges and of charge neutralisation effects, mixtures with peptide/suramin ratios of 1:1a nd 1:2w ere investigated throughout this study.
To determine the relative affinities of the peptide towards lipid and small-molecule bindingp artners, three-component mixtures differing only in the order of mixingo ft he components were tested. In general, spectralf eatures of the liposome-containing samples more closely resemble those of the suramin-loaded peptidet han those of the lipid-bounds tate, and indicate random coil-to-helix transition ( Figure 2a nd Ta ble S1). However,c lear differences potentially attributable to the bindingp reference of the peptide could be observed. For systemsw ithaC M15/suramin ratio of 1:2( Figure 2B and D), comparable spectra wereo btained for the two-component CM15·suramin complexes and the three-component mixtures in which the peptidec ompetes for the partners, (Sur + lipid) + CM15, thus suggesting the prevalence of peptide-drug binding over the lipid interaction. However,t he strongest signal, exceeding intensitiesf or the pure CM15·suramin complex, was detected with PC/PG liposomes when suramin was added to the lipid-boundp eptide( Figure 2D ); this argues for the highest apparent ordered peptide fraction with possibly the lowest level of aggregation for the (CM15 + PC/PG) + Sur mixture. This also points to the ability of suramin to enhanceh elical conformation even when the peptide is already attached to the lipid bilayer.A lternatively,v ariations in the spectrali ntensity might be coupled to aggregation induced by the small-molecule compound. Consistent with these observations, although the helical character of the peptide is clear,t he intensityo ft he CD signal is rather low for most of the three-component mixtures but especially with the 1:1C M15/suramin ratio (Figure2Aa nd C);this could be indicative of higher levels of aggregation. From the CD spectralf eatures observed for the two-and three-component systems, additional information about peptide binding characteristics could be derived. The p-p*b and minimum of the PC/PG-bound CM15 is below 210 nm, whereas for the suramin-associated peptide it is at around2 10 nm (Figure 2C and D) . This wavelengths hift could reflect polarity changes in peptide backbone surroundings. Specifically,t he hydrophobic environmentp rovided by PC/PG liposomes could increasethe excitation energy of the p-p*t ransitions, resulting in ab lue shift. Conversely,t he more polar aqueous phase aroundt he CM15·suramin complexes could cause ar ed shift of the p-p*p eak. In light of this consideration, spectral features witnessed for three-componentmixtures showingnon-reduced signals- Figure 2B and D, (Sur + lipid) + CM15 and (CM15 + PC/ PG) + Sur-arec onsistent with ab inding scenarioi nw hich peptidec hains are not inserted into the nonpolar interior of the lipid bilayer but rather are exposed to the bulk aqueous phase. Furthermore, in view of suramin association to the vesicles as suggested above,p eptide-suramin interaction might occur at the liposome surface.
CM15·suramin complex aggregation revealed by DLS and electron microscopy
To monitorf ormationo fm olecular aggregates,D LS measurements were conducted. As previously indicated,
[5a] large associates appeared in the case of the two-component CM15/suramin system. They showed hydrodynamic diameters in the lowmicrometre range, also confirmed here for both 1:1a nd 1:2 peptide/suramin ratios ( Figure 3 , Ta bles S2 and S3). The phenomenonw as explained in terms of mutual chargen eutralisation in complexes made up of the cationic CM15 and its anionic partner, resulting in less hydrophilic adducts that were prone to aggregation in the aqueous environment.
Peptide binding to the lipids induced no detectable changes in the correlation function, so al iposomes izeo f1 00 nm was determined for the vesicle/peptide mixtures. Similarly,a ddition of suramin to the model membranes caused no perturbation of the curves. However, for the three-component systems, a shift of the correlation function to higher decay times is consistent with formation of aggregates with diameters greater than 100 nm. The estimated aggregate size, in the high-nanometre to low-micrometre range, is similar to that measured for CM15·suramin complexes. Large-sized associatesw ere clearly detectedi nt he presence of PC liposomes, but this was not so pronounced with PC/PG liposomes. In general,m ixtures of preincubated peptide and drug with subsequent addition of lipid vesicles showed the greatest propensity to form large aggregates.A sa ne xceptiont ot his, all three-component systems displayed large-sized particles in the presence of neutral PC liposomes,t hus highlighting the importance of peptide-drug chargen eutralisation in effective assembly.T he association process is also regulated by the CM15/suramin ratio, with the size distributions of the aggregates being found to be narrow- er in the case of the 1:2r atio than in that of the 1:1r atio (Tables S2 and S3). In line with this, no such dependence on the molar ratio was observed in the case of the anionic PC/PG vesicles.
Aggregate formation wasf urtheri nvestigated by transmission electron microscopy (TEM),p roviding additional information on the morphologyo ft he CM15·suramin complex. Consistent with the DLS results, TEM images for both 1:1a nd 1:2 peptide/drug ratios (Figure 4) showed formationso fu pt o1 -2 mmi nd iameter with ac haracteristic morphology.T hese displayed networks of sphere-like building blocks of % 50 nm interconnected by rather linear regions. As imilar associated state, depicted as ab eadlike branched morphology, was reported for the anticancer/antimicrobial peptideLL-37 in acomplex with self-RNA as detected by phase-contrast-light, scanning-electron and confocal fluorescencem icroscopy. [19] These findings suggest that cationic amphiphilic peptides such as CM15 and LL-37 might easily form complexa ggregates with anionic partnersb earing aromaticr ings with limited structural flexibility,s uch as drugs or nucleotides.I ts hould be noted that particles with this morphology are typical for the CM15·sura-min complex but wereo bserved neither in peptide-only nor in drug-only solutions.
Tryptophan fluorescence indicates altered environments in different lipid complexes
To obtain additional information on the CM15-suramin interaction in the presence of various lipid bilayers, fluorescencespectroscopym easurements were performed. Here we exploited the intrinsic tryptophan fluorescenceo ft he peptide, which sensitively reports binding events that lead to polarity changes in the local fluorophore environment.
The spectrum of the free peptidei sc haracterised by an emission maximum at 357 nm ( Figure 5 ), consistentw ith a water-accessible tryptophan of ad isordered peptide. Upon addition of the liposomes, the membrane-bound state was easily detectable through the blue shift of the maximum. This phenomenon is typical for at ryptophan residue inserted in am ore nonpolare nvironment shielded from the aqueous phase. The effect was more pronounced, accompanied by as ignificant intensity increase, in the case of the negatively charged PC/PG liposome. In contrast, the rather wide maximum in the case of the PC-bound peptides uggests the coexistence of two tryptophan populations with different environments. These results agree well with stronger peptide binding associatedw ith more intimatei nteraction with PG-containing bilayers than in the case of the neutralP Cl iposome, and are also in line with the CD-based considerations above.
Titration of CM15 with suramin resulted in ar educed emission intensity,i ndicating an earbyq uencher group in the complex ( Figure 6A ). If the structure of suramin (Scheme 1) is considered,t he aromatic naphthyl moieties could account for the effect, although ligand-binding-induced helical folding could also lead to tryptophan quenching due to enhanced rigidity and closer proximity of adjacent side chains.
[20] Nevertheless, the moderate dose-dependent intensity decrease, leadingt o almostc omplete fluorescencel oss at 50 mm drug concentration ( Figure 6A) , is characteristicf or the CM15-suramin interaction. Similarly,n early complete loss of fluorescenceu pon addition of suramin was reported for the recombinantp rion PrP protein anda ttributed to suramin-induced aggregation, [21] a phenomenon also detected here for CM15, as discussed above.
For purposes of comparison, the same experiment was carried out with the non-binding tryptophan control N-acetyltryptophanamide (NATA), whichd oes not form stable complexes with suramin and can consequently reflect dynamic quenching and/or inner filter effects. In this case ( Figure 6B )intensity loss was much weaker,a nd the lack of static binding of NATA to liposomes or suramini se vident from the slight linear suramin-dependent intensity decrease, which occurred to the same extent both in the presence andi nt he absence of lipid vesicles.T hus, the difference in quenching efficiency observed on comparing the effects of suramin on NATA and CM15 could be accounted for by the peptidebinding of the drug.
When suramin titration was performed on lipid-loaded peptide, more effective quenching was observedt han in the case of the lipid-free state, thus suggesting ad ifferent peptidedrug binding mode ( Figure 6B ). For the PC system,t he fluores- cence loss was % 85 %a t1 :1 and complete at ap eptide/ suramin ratio of 1:2.5.P C/PG liposomes showed intermediate behaviour closer to that of the free peptidet han that of the PC-bounds tate. Ap ossible explanationf or the phenomenon could be binding of suramin to the lipid bilayer separately from the peptidea nd/or to the vesicle-bound peptide, resulting in ab etter relative positioning of the putative suramin quencher group for accessing the peptide fluorophore. If the suramin naphthyl groups were assumed as the quenchers, detection of more efficient quenching in the case of the PCbound peptidew ould requiret ryptophan situated closer to suramin and/or in am ore suitable relative orientation of the two rings on the two components enabling better contact than in the case of the pure peptide·drug complex.T his could relieve some "lifting out" of the lipid-loaded peptide inserted to some depth into the bilayer,w hich could be easier in the case of the PC-boundp eptide, with al ooser contact to the vesicle. In contrast, the tryptophan in the peptideb ound more tightly to the PC/PG liposome could remain more firmly incorporated,a lthough still located closer to the suramin quencher part. In the latter case, drug bindingw ould probablyb el ess favoured because of electrostatic repulsion between the negatively charged suramin sulfonyl and PG head groups. Nevertheless, this binding mode assumesp referred interaction between the N-terminal part of CM15 and the middle part of suramin (Scheme 1) in the CM15·suramin complex, and this was indeed predicted by meanso facomputational approach in our group. [22] Moreover, similar binding characteristics involving the membrane-associated drug could be deduced from CD findings (see above) and from IR spectroscopy experiments (see below).
Although the ability of suramin to quench af luorophore such as at ryptophan has been demonstrated herea nd is reported in ref. [21] ,s uramin also has intrinsic fluorescence properties related to its naphthylamide moiety.W hen excited separately from tryptophan at 315 nm, suramin emission with a maximum near 400 nm showed remarkablee nhancements of up to tenfold in the presence of protein binding partners. [23] However, when excited at 295 nm-the wavelength used here for exciting tryptophan-the weak emission peak developing at % 400 nm showedn os ensitivity to drugi nteractions with CM15 or vesicles (data not shown).
In summary,f luorescenced ata suggest perturbed CM15-suramin interaction with different relative conformations of the peptide towards the binding partners in the presence of lipid bilayers. Titration results obtained for lipid-boundC M15 are not compatible with simple peptide displacement from the vesicles by suramin.
Peptide partition between liposome-boundand suramincomplexed states suggested by IR spectroscopy
The interaction between CM15 and lipid assemblies such as vesicles has been studied by meanso fI Rs pectroscopy by several groups.
[2d, 24] Bastos et al.
[24d] investigated the interaction betweenC M15 and liposomes formed from saturated lipids that were also shorter than those (PC/PG) used here. By monitoring lipid carbonyl stretchasafunctiono fi ncreasing peptide concentration, it was reported that the bilayer retained significant order in the presence of the peptide.
Parts of IR spectra involving lipid carbonyl (ca. 1735 cm )i nt he presence of the peptides uggests that the polar/nonpolar interface in the lipid bilayer could be involved in the interaction in the cases both of PC and of PC/PG vesicles.
More pronounced changes were witnessed in the amide I band of the peptideu ponl ipid binding. Beside the main band at 1660 cm À1 assigned to the disordered/helical fraction,anew band component appeared ata round 1684 cm À1 in the presence of liposomes. In an early study on interactions between melittin or melittin fragments and PC vesicles, Brauner et al. [25] observedv ery similar spectralf eatures. They speculated that the band at 1685 cm À1 arosef rom peptides assembled at the lipid surface in an extended conformation. [25] In general, there is some controversy relatingtoresultsavailable for CM15 and other membrane-active peptides when peptide orientation relative to the bilayer is considered. It has been argued that perpendicular insertionc onnected mainly to pore formation by the surface-associated peptidem ight occur above at hreshold peptide concentrationa nd peptide/lipid ratio. [3, 5c, 24d] The structural changes associated with CM15-suramin interaction can also be monitored by IR spectroscopy (Figures 7  and 8 ). An important advantage of the methodi sthat the signal is not complicated by spectral perturbationsd ue to the presenceo fa ggregates. Changes in the amide Ia nd amide II bands ( Figure 7A )s uggestaprotein-like complex structure with predominant helical conformation (corroborated by the amide Ip eak centred at 1655 cm À1 )c onnected to suramin-induced oligomerisation/aggregation. Similaro bservations have also been made by other methods.
[5a] In addition, ar emarkable feature of the CM15·suramin complex is as harp peak at 1040 cm À1 that is markedly separated from the buffer phosphate vibrations( Figure 7B ). This band can be assigned to the in-phaseS ÀOs tretching of the sulfonyl groups in the complexed suramin,a sa lso observedf or suramin oligomers. [26] Thus, the extra band at 1040 cm À1 could be used as an IR marker for identification anda pproximate quantification of CM15·suramin complex formation. We have to point out that at the suramin concentrationsu sed-80a nd 160 mm-no such local crowding was detected in the absence of CM15. This is in agreement with NMR data that support the prevalence of monomers at 0.5 mm concentration but oligomerisation at 5mm. [27] On the basis of the spectral changes experienced for the two-component systems, in the three-component mixtures we focusedo nt he evolution of the amide Ib and component at 1684 cm
À1
,a sw ell as on the band at 1040 cm
,a sm easures of the peptide-lipid and peptide-drug interactions, respectively.
Firstly,l iposome systems with 1:2p eptide/suramin ratios were analysed (Figure 8 ). These revealed substantial differences when the mixing order of the components was varied. Upon addition of suramin to PC-boundC M15, the intensity of the shoulder amide Ib and at 1684 cm À1 decreases ( Figure 8A ), indicatingc ompetition of lipid and drugf or the peptide. However,w hen suramin is added first to CM15 or PC, suppression of the amide Ib and component is nearly complete (Figure8A), thus suggesting highera ffinity of CM15 towards the drug. A similar trend was observed for the extra band at 1040 cm À1 ( Figure 8B andT able S4) .
From the band intensities, the largesta mount of CM15·sura-min complex was formed when the peptideand the small-molecule compound were mixed first. In the case of administration of suramin to the PC-bound peptide, the affinity of CM15 towards the liposomesi s, however,o nly partially abolished, in parallelw ith reduced CM15·suramin complex formation.
When addition of suramin to liposomes was followed by incorporation of the peptide,C M15·suramin complex formation was still remarkable and no redistribution towards liposomes was witnessed. Ap ossible explanation for this could be lipid binding of CM15 being strong enough to interfere with suramin interaction, so the liposome-loaded peptidec annotp articipate in complex formation with the drug. However,t his binding scenarioi sn ot in full agreement with CD and DLS results indicating as ignificant fraction of CM15/suramin associatesi n the presence of neutral vesicles,w hichp oints to ab inding event in which suramin can interactw ith liposomes and/or lipid-bound peptidea ss uggested by the CD and fluorescence results. Indeed, liposome-associated suramin causes perturbation of the lipid head group region, as indicated by as hift of the lipid asymmetric phosphate vibration (nPO as )a t1 240-1250 cm
. With reduced suramin concentrations at the CM15/suramin ratio of 1:1i nt he PC system ( Figure S2 ), weaker peptide-liposome interaction was observed in all of the three-component (Figure S2 A) . The latter suggests as light lifting of CM15 from the polar/nonpolar boundary of the bilayer upon suramin addition. On the other hand, the formation of the CM15·suramin complex is less significant (Figure S2 B ) than in the 1:2C M15/suramin case ( Figure 8B ). Nevertheless, the largesta mount of peptide·drug complexw as indicated when vesicles were added to theC M15/suramin mixture (Table S4) .
With use of the PC/PG liposome system to mimic the negative chargeo fabacterial membrane, both similarities to and differences from the neutralP Cs ystem were found. At a1 :2 peptide/suramin ratio (Figure 8) , addition of suramin diminishes the amide Ib and shoulder at 1684 cm À1 significantly but not completely ( Figure 8C) . Furthermore, the marker band of CM15-suramin association at 1040 cm À1 ( Figure 8D )i sl ess pronounced (Figure8B). This is in line with the considerations above:n amely the binding of CM15 to negatively charged liposomesb eing stronger than that to neutrall ipids, so peptide· drug complex formation is more hindered in the former case (see also Ta ble S4). From these results, it can be concluded that in the three-component systems there is competition for CM15 between binding to the liposomes urface or complex formation with suramin. However, the (CM15 + PC/PG) + Sur mixture behaves exceptionally.F or this system, both peptide interactions seem to be diminished, accordingt or educed band intensities at 1685 and 1040 cm
.M oreover,aslight shift of the lipid carbonyl band from 1735 to 1737cm À1 is observed;this occurs only for this mixture combination.
In contrastt oP C/PG liposome systemsw ith a1 :2 peptide/ suramin ratio, no shifto ft he lipid carbonyl group was observed for any mixture with a1:1 ratio (Figure S2 C) . Alterations in the 1684 cm À1 marker band suggestt hat in cases in which suramin is added to the PC-bound peptide, binding of CM15 to the liposome is still strong (Figure S2 C) . Simultaneously,f ormationo fC M15·suramin complex is also hindered,a sc onfirmedb yt he significant intensity loss of the "complex marker" band at 1040 cm À1 ( Figure S2 Da nd Ta ble S4). To summarise the findings obtained from IR measurements, our results point to dominant peptide-drug interaction when the lipid is added to the preformed CM15·suramin complexes. This preference is stronger at aC M15/suramin ratio of 1:2a nd more relevantf or the neutral PC system than for the charged PC/PG system. Vesicle attachment of CM15 could be strong enough to inhibit CM15·suramin complexf ormation;h owever, 
Bindingdeterminants in the three-component systems
By combining the results obtainedf rom the biophysical measurements, we can conclude ag eneral binding scenario in three-component CM15/suramin/lipid systemsi nw hich CM15 forms ac omplexw ith suramin at the expense of binding to liposomes. However, not all spectral changes observedc ould be explained simply in terms of peptide displacement.P erturbations in the lipid head group region detected by IR spectroscopy and suggested by fluorescenceq uenching point to possible binding of suramin to the vesicles or even to lipid-bound peptide, allowing the formation of dynamic complex associates. In these assemblies, the peptidec ould be extruded from the polar/nonpolar boundary of the lipid bilayer but might preserve looser contact with the less buried regime of the lipid head group region facing the aqueous phase.
Moreover,o ur findings point to the importance of mixing order in peptideb inding preference:t hat is, the binding partner that comes into contactw ithC M15 first. Peptidei nteraction with the small-molecule compound could dominate over liposomeb inding when the lipid is added to preformed CM15·suramin complexes.H owever,t he binding preference is also controlled by peptide/suramin ratio as well as by vesicle composition, mainly driven by electrostatics. CM15 and suramin bear + 6a nd À6n et charges, respectively,s oc omplex formation could be initiatedb ye lectrostatic attraction between peptidea nd drug. Consistently with chargen eutralisation at an equimolar ratio and the negative overall charge of the complex at higher suramin concentrations, higher degrees of peptide partition towards complexf ormation with suramin leading to more significant aggregation were detected at 1:1C M15/ suramin ratio and in the case of the neutral liposome system. In contrast, vesicle attachment of CM15 could inhibit interaction with the drug when suramin meets the peptide associated tightly to the negatively charged membrane.
Our results suggestedt hat electrostatic forces play ap ivotal role in the initiation of peptideb inding and assembly.T his is consistentw ith previouss tudies in which it was assumed that electrostatics are ak ey factor in AMP-membrane interactions.
[24d] However, in view of the amphiphilic nature of all partners (CM15,s uramin, lipids), hydrophobic interactions could also contributet ot he binding energetics. Indeed,C Ds pectra, tryptophan fluorescencea nd lipid carbonyl vibration indicated peptider egionsr esiding close to the nonpolar interior of the lipid bilayer.I nc ontrast, CD and IR spectroscopicr esults suggested am ore polar environment for suramin-bound CM15 even in the presence of vesicles.
Variationsinpeptidestructure monitored by CD and IR spectroscopy are compatible with ar educed content of the membrane-active peptidec onformation in the presence of suramin, with this appearing to be valid even when the ability of suramin to interactw ith biomembranesi st aken into account.T o test the biological relevance of the above interactions and their potential in altering bioactivity,i nv itro antibacterial and cytotoxicity assays wereperformed.
Altereda ntibacterial activitya nd cytotoxicity of CM15 in the presence of suramin
To understand the biological relevance of the AMP·drug complex formation,a ntibacterial effects and cytotoxicity on human cells wereprobed with CM15 premixed withsuramin.
On the tested Escherichia coli strain, CM15 showed ar emarkable antibacterial effect, as indicated by the fact that no bacterial growth was detected at peptidec oncentrationsa sl ow as 5 mm.I nt he presence of suramin, however,t he peptide's efficiency was significantly decreased,w ith bacterial growth being observede ven at higher CM15 concentrations of 10-40 mm ( Figure 9A ). To provide am ore detailedp icture on the effects of suramin, bacteria were treated with 5 mm peptidep reincubated with excess suramin. As trong impact of the drug on the antibacterial efficacy of CM15 is evident,w ith significantly greatera mounts of the bacterial cells surviving when CM15 was added with suramin ( Figure 9B ). Furthermore, increasing suramin concentrations resulted in higher relative bacterial growth. Specifically,t his value at ap eptide/suramin ratio of 1:2 was approximately half that at 1:8( Figure9B).
The membrane-disruptinga ctivity of CM15 was also tested with human cells, specifically with MonoMac6 monocytes and red blood cells (RBCs). Cells were treated with CM15 in the absence or in the presence of suramin at 1:1a nd 1:2p eptide/suramin ratios. With the monocyte cell line, CM15 alone was found to be cytotoxic at ar elativelyl ow concentration( IC 50 = 7.6 mm, Figure 10 A), whereas when it was administered together with suramin the effect was substantially decreased.P eptide (Figure 10 B) ;t his is consistent with the reduced haemolytic activity of the hybrid peptide relative to its parent melittin. [28] In the presence of suramin, no haemolysis was observed (HC 50 > 200 mm,F igure 10 B). It is to be noted that suramin alone at concentrations up to 100-200 mm showednoeffect on these cells (Figure 10 Aand B), which indicates that reduced peptidec ytotoxicity is directly connected to CM15·suramin complex formation.
In an early work, an effective concentrationo f1 0mm and typical drug dosage of 0.3 mm were reported for suramin. [11] In ar ecent study,p atients were treated withs uramin at plasma concentrations in the 140-190 mm range and the drug was cleared with a4 0d period half time. [29] Because suramin can reach high levelsi nv ivo, the interactions investigatedh ere are likely to occur in the human body.
Conclusion
We have investigated the structural and functional effectso f the therapeutic drug suramin on the membrane-active antimicrobial peptideC M15 by ac ombination of severalb iophysical methods. On the basis of the structurald ata supported by in vitro binding assays, our findings are compatible with am odel delineating formation of dynamic complexa ssociates of the peptidep opulated in lipid-bounda nd/or drug-loaded forms.
CM15 partitioni sg overned mainly by charge neutralisation effects controlled by suramin-to-peptider atio and lipid bilayer composition. We have also demonstrated that interaction with suramin changed peptidef unctiona ppreciably,a si llustrated by significantly reduced antimicrobial activity on Gram-negative bacteria and diminished cytotoxicity towards mammalian cells. In view of the low effective concentrations for both CM15 and suramin, high drug plasma levelsd uring medical treatments and locally accumulated AMPs, suramin and AMP levels can fall in the range used in this study. On the bases of these findings and of severalo ther small-molecule-AMPi nteractions demonstrated recently in our group, it is proposed that naturalA MPs and host defence peptides will regularly experience alteration of their structuresa nd functions in the complex in vivo environment-an aspectt ob ec onsidereda nd potentially exploited during future treatments andd rug design.
Experimental Section
Peptide solution:C M15 was synthesised in the solid phase by using an automated peptide synthesiser and as tandard Fmoc/tBu strategy.P eptide product was characterised by analytical RP-HPLC, mass spectrometry and amino acid analysis (see the Supporting Information for more details). Lyophilised CM15 powder (trifluoroacetate salt) was dissolved in high-purity water at the indicated concentration (not higher than 1mm), aliquoted and stored frozen at À18 8Cu ntil use (no longer than afew weeks).
Suramin solution:S uramin powder (sodium salt, Calbiochem) was dissolved in high-purity water at the indicated concentration (not higher than 1mm), aliquoted and stored frozen at À18 8Cu ntil use.
Lipid solutions: High-purity synthetic 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-[phosphorac-(1-glycerol)] (DOPG) were purchased from Avanti Polar Lipids, Inc. Liposomes were prepared by the lipid thin-film hydration technique. Lipids were dissolved in chloroform (LabScan, Hungary) containing methanol (Reanal, Hungary,5 0vol %) and then evaporated with the aid of ar otary evaporator.T he resulting lipid film was kept under vacuum for at least 8hto remove residual traces of solvent. The dried lipid film was hydrated with the assay buffer.A fter repeated heating (37 8C) and cooling (À196 8C) steps (at least 10 times), the solutions were extruded through polycarbonate filters of 100 nm pore size (at least 11 times) with use of aL IPEX extruder (Northem Lipids, Inc.,C anada). Final lipid concentration was 13 mm.F or mimicking mammalian and bacterial cell membranes, pure DOPC and DOPC/DOPG (80:20, n/n%) were used throughout the study.
Assay conditions:T om imic physiological conditions, the assay buffer used throughout the study was isotonic phosphate-buffered saline [PBS, phosphate (10 mm), NaCl (137 mm), KCl (3 mm), pH 7.4],p urchased from Sigma-Aldrich. For measuring CD spectra, ab uffer free of chloride ions [CD buffer,N ap hosphate (10 mm), Na 2 SO 4 (100 mm), pH 7.0] was frequently used, allowing collection of spectra down to 190 nm.
In investigation of three-component systems, the order of addition of the components was varied. This involved preincubation of two compounds (Comp1 and 2) for 3-4 min, followed by the incorporation of the third one (Comp3). The corresponding labelling used throughout the text is (Comp1 + Comp2) + Comp3. Circular dichroism (CD) spectroscopy:C Ds pectra were collected with aJ ASCO J-1500 spectropolarimeter at room temperature in 0.1 cm path-length cylindrical quartz cuvettes (Hellma, USA). Peptide CD data were collected in continuous scanning mode between 190 and 260 nm at ar ate of 50 nm min À1 ,w ith ad ata pitch of 0.5 nm, response time of 4s,1nm bandwidth, and three accumulations. CD curves for peptide, peptide/drug, peptide/liposome and peptide/liposome/drug samples were corrected with ab lank buffer solution. Titration with suramin in the presence and in the absence of liposomes was performed in duplicate with use of CD buffer and as as ingle experiment in PBS. To estimate CM15 secondary structure content under various conditions, the software provided by the BeStSel (Beta Structure Selection) website (http:// bestsel.elte.hu) [30] was used. Data points are given as means AE standard errors of means (SEMs).
Dynamic light scattering (DLS):M ean hydrodynamic diameter (D h ) and polydispersity were measured at 20 8Cw ith aW 130i dynamic light scattering device (DLS, Avid Nano, Ltd.,H igh Wycombe, UK) with ad iode laser (660 nm) and ap hotodiode detector.L owvolume disposable cuvettes with 1cmp ath length (UVette, Eppendorf Austria, GmbH) were used. Samples containing peptide (20 mm)a nd various amounts of drug and liposomes were measured in af inal volume of 80 mLi nP BS. The time-dependent autocorrelation functions were measured for 10 s, this was repeated ten times, and the average distributions were reported. The analysis of the measurement data was performed with the iSize 3.0 software, supplied with the device.
Attenuated total reflection (ATR) FTIR:F TIR spectroscopic measurements were conducted with aV arian 2000 FTIR Scimitar spectrometer (Varian, Inc, US) fitted with al iquid-nitrogen-cooled mercury/cadmium/telluride (MCT) detector and a" Golden Gate" singlereflection diamond ATRa ccessory (Specac, Ltd, UK). The sample (5 mL) was mounted onto the diamond ATRs urface, and the spectra were collected (2 cm À1 resolution and 64 scans) from dry films (after slow evaporation of the buffer solvent under ambient conditions). Prior to spectral evaluation, ATRc orrection was performed and the corrected spectra were smoothed with use of the Savitzky-Golay algorithm (polynomial degree = 2, number of points = 17) and the GRAMS/32 (Galactic, Inc.,U SA) software package.
Fluorescence spectroscopy:S pectra were recorded with aJ obin Yvon Fluoromax-3 spectrofluorimeter (3 and 5nme xcitation and emission slits, respectively), at 25 8Ci nP BS. To test peptide interaction, the tryptophan fluorophore of CM15 was excited at 295 nm and emission was monitored from 310 to 400 nm. Binding assays were carried out with CM15 at 1 mm in the presence and absence of liposomes being titrated with increasing amounts of suramin up to 50 mm.T oc orrect for spectral contribution of the liposomes and suramin, appropriate blank spectra (recorded for solutions containing no fluorophore but lipid and drug at the same concentration) were subtracted. Peptide titrations were performed in duplicate; data presented are means AE SEMs.
Transmission electron microscopy (TEM):F or direct visualisation of the structure and morphology of the sample, TEM images were obtained with aM orgagni 268D instrument (FEI, The Netherlands). Ad roplet (2 mL) of the sample prepared in PBS was pipetted onto a2 00 mesh copper grid with as upport film made of formvar. Excess liquid was removed after a2 0s contact time. Phosphotungstic acid (5 %) was added immediately as contrast material; then, after ac ontact time of 10 min, excess liquid was again removed and the sample was left to air-dry.
Antibacterial test, cytotoxicity and haemolytic assay:T he antibacterial effect of CM15 in the presence or in the absence of suramin was measured with E. coli strain DSM 1103. Bacterial lyophilisate was resuspended in Bouillon broth and cultured in ab lood agar plate for 24 h. To test peptide efficacy,0 .5 McFarland standard was diluted 50 times, and bacterial suspension (100 mL) was then plated on a9 6-well U-bottomed plate. Lysogeny broth (LB) was used as culture medium. CM15 solutions alone or together with suramin were added to the wells in af inal concentration of 40, 20, 10, and 5 mm for each compound. Plates were read after 24 hi ncubation. All samples were measured in quadruplet;d ata are means AE SEMs.
Cytotoxic effects of CM15 were measured with the MonoMac6 human monocytic cell line (DSMZ, ACC 124), widely used and accepted as model cells for assays of cytotoxicity,m embrane damage and cellular uptake of compounds such as peptides or drugs. [31] Prior to the treatment, cells were cultured in serum-free RPMI medium and plated (15 000 cells, 100 mL/well) in af lat-bottomed 96-well plate. CM15 was dissolved in serum-free medium at af inal concentration of 200 mm.S uramin was added to the peptide solution at 1:1or1:2 molar ratio. Cells were treated with serial dilution of CM15 or CM15/suramin mixtures over the concentration range of 0.8-100 mm in triplicate. Cells were incubated with the compounds for 1.5 h, and cell viability was then tested by use of the (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
[32] Briefly,M TT solution (45 mL) was added to each well (2 mg mL
À1
,d issolved in serum-free medium). After 3.5 hi ncubation, plates were centrifuged at 430 g for 5min, and the supernatant was carefully aspirated with aG 30 needle. The precipitated purple crystals were dissolved in DMSO (100 mL), and after 10 min agitation the absorbance was determined at 540 and 620 nm with use of an ELISA plate reader (iEMS Reader,L absystems). Cytotoxicity,e xpressed as ap ercentage as af unction of peptide concentration, was plotted, and IC 50 values were determined. Data are means AE SEMs (n = 3).
For haemolytic activity assay,p eripheral blood from ah ealthy volunteer (purchased from the Hungarian National Blood Transfusion Service, Budapest, Hungary) was collected in vacuum tubes containing sodium citrate as anticoagulant (Vacuette, 9NC). Tubes were centrifuged (430 g,5min) and the pellet was washed twice with PBS. PBS was added to the pellet to yield af inal RBC suspension (4 %, v/v). Stock solutions of the compounds were diluted in PBS and twofold serial dilution series were prepared (final concentrations 1.6-200 mm). RBC suspension (100 mL/well) was placed in a 96-well U-bottomed cell culture plate and mixed with peptide solution (100 mL). The plates were incubated for 1.5 ha t3 78C. After centrifugation (430 g,5 min), the supernatant (50 mL) was transferred to af lat-bottomed microtiter plate and absorbance was measured at 414/450 nm with an ELISA plate reader.P ercentage haemolysis was plotted against peptide concentration, and HC 50 values were determined. Data are means AE SEMs (n = 3).
To analyse statistical significance (p), the Student t-test was performed by using GraphPad Prism.
